Literature DB >> 8551055

Epidermal growth factor receptor in human breast cancer comparison with steroid receptors and other prognostic factors.

M Cerra1, L Cecco, M Montella, F Tuccillo, P Bonelli, G Botti.   

Abstract

The relationship between epidermal growth factor receptor (EGFR) status and various prognostic factors was investigated in 70 human breast cancer specimens. Epidermal growth factor receptor was determined by radioligand binding assay, standardized by the EORTC Receptor Study Group, using hydroxyapatite to separate receptor-bound and free ligand. The percentage of EGFR positivity was 80% when the cutoff was set at 5 fmol/mg of membrane protein; this percentage was among the highest hitherto reported. Regression analysis of EGFR versus ER and PR levels confirmed an inverse relationship between EGFR and ER (p = 0.022) as well as between EGFR and PR (p = 0.024). Univariate analysis of the EGFR data stratified according to steroid hormone receptor status showed EGFR to be negatively associated with ER and PR. No association was found between EGFR and menopausal status, axillary lymph node involvement, tumor size, and differentiation grade. A direct association between EGFR status and Ki-67 positive cell rate could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8551055     DOI: 10.1177/172460089501000302

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  5 in total

1.  Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Authors:  Dongwei Zhang; Ana M Tari; Ugur Akar; Banu K Arun; Tiffany A LaFortune; Rene Nieves-Alicea; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2010-11-02       Impact factor: 6.261

2.  Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Authors:  Dongwei Zhang; Tiffany A LaFortune; Savitri Krishnamurthy; Francisco J Esteva; Massimo Cristofanilli; Ping Liu; Anthony Lucci; Balraj Singh; Mien-Chie Hung; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

3.  Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

Authors:  Dongwei Zhang; Ashutosh Pal; William G Bornmann; Fumiyuki Yamasaki; Francisco J Esteva; Gabriel N Hortobagyi; Chandra Bartholomeusz; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

4.  Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.

Authors:  Lixin Zhang; Jason A Ngo; Michael D Wetzel; Dario Marchetti
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

5.  Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Authors:  Hiroko Masuda; Keith A Baggerly; Ying Wang; Takayuki Iwamoto; Takae Brewer; Lajos Pusztai; Kazuharu Kai; Takahiro Kogawa; Pascal Finetti; Daniel Birnbaum; Luc Dirix; Wendy A Woodward; James M Reuben; Savitri Krishnamurthy; W Symmans; Steven J Van Laere; François Bertucci; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Breast Cancer Res       Date:  2013-11-25       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.